ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.56 +0.42%

+$0.04 today

Market cap
$3.01B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.17M

Average 7.07M

ADMA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

ADMA Biologics, Inc.NASDAQ: ADMA

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue declines year over year

Q2 FY2026 cost of revenue of $38.12M fell 30.4% year over year, behind the -18.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 13.0% from the prior quarter. Over 3 fiscal years it compounded at +22.3% a year.

Context

  • Cost of revenue amounted to 42.6% of revenue in FY2025, down 5.9 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -30.4% toward the trailing-twelve-month pace of -18.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$38.12M+13.0% QoQ
Last fiscal yearDec 2025
$217.41M+5.1% YoY
LTMJun 2026
$180.81M-18.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.4%——
1 year+5.1%——
3-year CAGR+22.3%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
217.41M USD
Year-over-year change
+5.1%
4-year CAGR
+28.5%

Cost of Revenue vs competitors

How ADMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -18.9% is the 3rd highest of 4, against a peer median of +3.6%.
  • Cost of revenue amounts to 35.3% of revenue for ADMA, versus a peer median of 8.0%.
ADMA Competitors
Cost of Revenue for ADMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GRFSGrifols, S.A.LTM Jun 2026€4.66B EUR+3.6%+6.5%62.8%
ADMAADMA Biologics, Inc.LTM Jun 2026$180.81M USD-18.9%+22.3%35.3%
IVVDInvivyd, Inc.LTM Mar 2026$4.46M USD+81.8%—8.0%
ABUSArbutus Biopharma CorporationLTM Mar 2026$33K USD-99.8%—0.0%
Peer median (excluding ADMA) —+3.6%+6.5%8.0%

Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue80.94M154.08M258.22M426.45M510.17M
Cost of Revenue79.77M118.82M169.27M206.9M217.41M
Gross Profit1.17M35.27M88.94M219.55M292.77M
Gross Margin1.4%22.9%34.4%51.5%57.4%
Research & Development3.65M3.61M3.3M1.81M4.76M
Selling, General & Admin42.9M52.46M59.02M74.12M91.58M
Operating Expenses59.55M74.63M67.31M80.57M101.32M
Depreciation & Amortization5.5M7.11M8.33M8.05M8.1M
EBITDA(53.1M)(39.51M)5.12M147.69M197.86M
EBITDA Margin-65.6%-25.6%2.0%34.6%38.8%
Operating Income(58.37M)(39.37M)21.63M138.98M191.44M
Operating Margin-72.1%-25.5%8.4%32.6%37.5%
Interest Income34.53K44.83K1.62M2.1M1.87M
Interest Expense13.06M19.28M25.03M13.93M7.11M
Other Income / Expenses(13.27M)(26.54M)(49.87M)(13.27M)(8.79M)
Income Before Tax(71.65M)(65.9M)(28.24M)125.71M182.66M
Pre-Tax Margin-88.5%-42.8%-10.9%29.5%35.8%
Income Tax Expense000(71.96M)35.73M
Net Income(71.65M)(65.9M)(28.24M)197.67M146.93M
Net Margin-88.5%-42.8%-10.9%46.4%28.8%
EPS (Basic)(0.61)(0.43)(0.13)0.850.62
EPS (Diluted)(0.61)(0.43)(0.13)0.810.60
Weighted Avg Shares139.58M197.87M223.98M233.08M238.3M
Weighted Avg Shares (Diluted)139.58M197.87M223.98M243.34M244.9M

ADMA Biologics, Inc.

NASDAQ:ADMA

Intrinsic Alpha fair value

Locked

Current Price

$13.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.